{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.47","upperLimit":"13.83","value":"8.51"},{"groupId":"OG001","lowerLimit":"5.55","upperLimit":"11.07","value":"6.47"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"39"}],"units":"Participants"}],"description":"The time between the date of first response to the date of the first objectively documented tumor progression as assessed by the investigator according to International Myeloma Working Group (IMWG) criteria or death due to any cause prior to subsequent anti-cancer therapy. Participants who neither progress nor die will be censored on the date of their last tumor assessment prior to subsequent anti-cancer therapy. Progression is 1) increase of 25% from lowest confirmed response value in specific Serum M-protein and Urine M-protein criteria and increase of FLC for patients with no measurable M protein in blood or urine at baseline and/or 2) appearance of a new lesion(s), \\>/= 50% increase from nadir in SPD of \\> 1 lesion, or \\>/= 50% increase in the longest diameter of a previous lesion \\> 1 cm in short axis.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab:\n\n* Cycles 1 through 4: 240 mg IV Days 1, 15 of each 28-day cycle.\n* Cycles 5 and beyond: 480 mg IV Day 1 of each 28-day cycle.\n\nPomalidomide:\n\n\\- 4 mg PO QD Days 1-21 of each 28-day cycle.\n\nDexamethasone:\n\n* Participants \\</= 75 years old: 40 mg PO Days (1, 8, 15, and 22) of each cycle\n* Participants \\> 75 years old: 20 mg PO Days (1, 8, 15, and 22) of each cycle.","id":"OG000","title":"Arm A: N-Pd"},{"description":"Pomalidomide:\n\n\\- 4 mg PO QD Days 1-21 of each 28-day cycle.\n\nDexamethasone:\n\n* Participants \\</= 75 years old: 40 mg PO Days (1, 8, 15, and 22) of each cycle\n* Participants \\> 75 years old: 20 mg PO Days (1, 8, 15, and 22) of each cycle.","id":"OG001","title":"Arm B: Pd"}],"paramType":"MEDIAN","populationDescription":"All responders (sCR, CR, VGPR, or PR) in Arm A and B. Data was pre-specified to be collected only in the N-Pd and Pd arms.","reportingStatus":"POSTED","timeFrame":"From randomization to the date of the first objectively documented tumor progression or death due to any cause prior to subsequent anti-cancer therapy (up to approximately 64 months)","title":"Duration of Objective Response (DOR)","type":"SECONDARY","unitOfMeasure":"Months"}